Jump to content

Search the Community

Showing results for tags 'Side Effects'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 28 results

  1. Severe hypocalcemia associated with denosumab (Xgeva or Prolia) in metastatic castration-resistant prostate cancer has been reported on the European Urology website (25/2/2015) Some practice points for physicians have been recommended here. Bone is the most frequent site of metastatic disease in prostate cancer, which can lead to skeletal-related events (SREs) such as pathologic fracture and cord compression. Denosumab is approved by the US Food and Drug Administration (and the TGA / PBS in Australia) for use in solid tumors with bone metastases to prevent or delay SREs such as new fracture and the need for radiotherapy to bone. The authors' case series suggested that a higher prevalence of severe and often prolonged hypocalcemia requiring hospitalization may occur in patients with metastatic castration-resistant prostate cancer in clinical practice. Hypophosphatemia was also commonly identified in cases of severe hypocalcemia. Increased disease burden and vitamin D deficiency were discernible risk factors. Patients with albumin-corrected calcium levels in the low normal range may also be at risk. Hospitalization for aggressive calcium and vitamin D replacement, calcitriol therapy, and correction of other electrolyte imbalances is encouraged for patients who experience severe hypocalcemia while receiving treatment. Denosumab (Xgeva or Prolia) is a unique monoclonal antibody inhibiting 'RANKL', as distinct from zoledronic acid, which is a second generation bisphosphonate, also widely used for bone protection in the context of extended androgen deprivation (ADT) and/or bone metastases. a clinical comparison of these two drugs can be found in this section of The Forum. Patients about to use or already using denosumab should discuss the issues raised above with their prescribing doctors, and should ensure that serum calcium and phosphate are being adequately monitored. Cheers, Alan B
  2. Denosumab (brand name Xgeva) is associated with a rare but well-known risk for severe hypocalcemia (very low calcium in the blood stream). The "New" Prostate Cancer InfoLink has an article about this risk which includes a very sensible warning: "If your doctor advises you that you would be appropriately treated with denosumab for prevention of skeletal-related events associated with advanced forms of prostate cancer (particularly in men with metastatic disease on long-term androgen deprivation therapy), you need to be sure that your serum calcium and vitamin D levels are monitored prior to initiation of therapy."
  3. Prostate Cancer Hormone Therapy Study Have you received hormone therapy treatment for prostate cancer? If so, you may be eligible to join an American Cancer Society funded study to test a program designed to help people with changes to memory, thinking and concentration following hormone therapy for treatment of prostate cancer. This study is done completely over the phone and internet and involves a brief screening to determine eligibility, 3 assessments/interviews, and 8 weeks of home-based computer use. For more information, please contact Lisa Wu at +1 (212) 824-7805 or lisa.wu@mssm.edu This study is approved by the Mount Sinai Institutional Review Board (GCO# 10-1352 approved through 6 April 2015) Dr Lisa Wu is an Instructor in the Department of Oncological Sciences in the Icahn School of Medicine at Mount Sina, New York, one of the leading medical schools in the United States. For a number of years Lisa's work has focused on research into quality of life issues around cancer patients experiencing cognitive difficulties after treatment. Lisa already has a number of men from Australia participating in this study. She is wanting to recruit more Australian men who have had hormone therapy treatment. Given the time difference, sending an email to Lisa is probably the easiest way to make initial contact.
×
×
  • Create New...